17.05.2018
MorphoSys AG DE0006632003
DGAP-News: MorphoSys Announces Presentation of Clinical Data on Proprietary Blood Cancer Programs at Upcoming EHA 2018 Conference
DGAP-News: MorphoSys AG / Key word(s): Conference/Study results
MorphoSys Announces Presentation of Clinical Data on Proprietary Blood
Cancer Programs at Upcoming EHA 2018 Conference (news with additional
features)
17.05.2018 / 15:01
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Planegg/Munich, Germany, May 17, 2018
MorphoSys Announces Presentation of Clinical Data on Proprietary Blood
Cancer Programs at Upcoming EHA 2018 Conference
MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX; Nasdaq: MOR; OTC:
MPSYY) today announced the publication of two abstracts on its proprietary
hemato-oncological drug candidates MOR208 and MOR202 submitted to the 23rd
European Hematology Association (EHA) Annual Meeting, to be held in
Stockholm/Sweden from June 14-17, 2018.
In a poster presentation, first clinical data from the exploratory phase 2
COSMOS trial with the Fc-engineered CD19 antibody MOR208 in combination with
idelalisib in chronic lymphocytic leukemia (CLL) and small lymphocytic
lymphoma (SLL), after discontinuation of an ibrutinib therapy, will be
presented. In an oral presentation, updated maturing data from a phase 1/2a
study with the CD38 antibody MOR202 alone and in combination with
pomalidomide or lenalidomide in relapsed/refractory multiple myeloma will be
presented.
"We are pleased that clinical data from trials investigating our proprietary
antibody programs MOR208 and MOR202 in indications with high medical need
were selected for presentation at the upcoming EHA conference," commented
Dr. Malte Peters, Chief Development Officer of MorphoSys AG.
Details about the abstracts from MorphoSys's proprietary programs MOR208 and
MOR202 accepted for presentation at EHA 2018:
Abstract Code: PF350
Two-cohort, phase II study in R/R CLL (COSMOS): First preliminary safety and
efficacy results of MOR208 treatment in combination with idelalisib in
patients who discontinued prior ibrutinib therapy
The poster presentation will include clinical results from the phase 2 study
COSMOS with MOR208 in combination with idelalisib (cohort A) in adult
patients with relapsed/refractory CLL who failed prior treatment with
Bruton's Tyrosine Kinase inhibitor (BTKi) ibrutinib.
The poster will be presented during the session "Chronic lymphocytic
leukemia and related disorders - Clinical" on Friday, June 15, 2018
5:30-7:00 pm CEST (11:30am-1:00pm EDT), in the poster area at the
Stockholmsmässan in Stockholm.
In addition, the abstract will be on display on the E-poster screens at the
conference from Friday, June 15, 2018, 9:30 am CEST (3:30 am EDT) to Sunday,
June 17, 2018 1:00 pm CEST (7:00 am EDT).
Abstract Code: S848
MOR202 with low-dose dexamethasone (DEX) or pomalidomide/DEX or
lenalidomide/DEX in relapsed or refractory multiple myeloma (r/r MM): A
phase I/IIa, multicenter, dose-escalation study
The oral presentation will include updated clinical data from the phase 1/2a
study with MOR202 alone or in combination with the immunomodulatory drugs
lenalidomide or pomalidomide, plus low-dose dexamethasone (DEX). The trial
is being conducted in pre-treated patients with relapsed/refractory multiple
myeloma.
The oral presentation will be given during the session "New therapeutic
strategies to improve the outcome of relapse/refractory plasma cell
disorders" on Saturday, June 16, 2018, from 4:15-4:30pm MEST (10:15-10:30am
EDT), in Room A1 at the Stockholmsmässan in Stockholm.
Additional information can be found at www.ehaweb.org, including the
abstracts.
About MorphoSys
MorphoSys is a late-stage, biopharmaceutical company devoted to the
development of innovative and differentiated therapies for patients
suffering from serious diseases. Based on its technological leadership in
generating antibodies, MorphoSys, together with its partners, has developed
and contributed to the development of more than 100 product candidates, of
which 28 are currently in clinical development. This broad pipeline spans
MorphoSys's two business segments: Proprietary Development, in which
MorphoSys invests in product candidates for its own account, and Partnered
Discovery, in which product candidates are developed exclusively for a
variety of Pharma and Biotech partners. In 2017, Tremfya(R) (guselkumab),
marketed by Janssen, became the first therapeutic antibody based on
MorphoSys's proprietary technology to receive marketing approval for the
treatment of moderate-to-severe plaque psoriasis in the United States, the
European Union and Canada. MorphoSys is listed on the Frankfurt Stock
Exchange and on the U.S. stock exchange Nasdaq, under the symbol MOR. For
regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R),
arYla(R),
Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R)
and LanthioPep(R) are registered trademarks of the MorphoSys Group.
Tremfya(R)
is a trademark of Janssen Biotech, Inc.
MorphoSys forward looking statements
This communication contains certain forward-looking statements concerning
the MorphoSys group of companies, including the progression of and upcoming
data presentations from the COSMOS trial in connection with MOR208 and
idelalisib and expectations regarding the development of MOR208 plus
idelalisib in CLL as well as in connection with MOR202 and pomalidomide and
lenalidomide each combined with dexamethasone and the development in
multiple myeloma. The forward-looking statements contained herein represent
the judgment of MorphoSys as of the date of this release and involve known
and unknown risks and uncertainties, which might cause the actual results,
financial condition and liquidity, performance or achievements of MorphoSys,
or industry results, to be materially different from any historic or future
results, financial conditions and liquidity, performance or achievements
expressed or implied by such forward-looking statements. In addition, even
if MorphoSys' results, performance, financial condition and liquidity, and
the development of the industry in which it operates are consistent with
such forward-looking statements, they may not be predictive of results or
developments in future periods. Among the factors that may result in
differences are the inherent uncertainties associated with competitive
developments, clinical trial and product development activities and
regulatory approval requirements, MorphoSys' reliance on collaborations with
third parties and other risks indicated in the risk factors included in
MorphoSys's Registration Statement on Form F-1 and other filings with the US
Securities and Exchange Commission. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking statements.
These forward-looking statements speak only as of the date of publication of
this document. MorphoSys expressly disclaims any obligation to update any
such forward-looking statements in this document to reflect any change in
its expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based or that may affect the
likelihood that actual results will differ from those set forth in the
forward-looking statements, unless specifically required by law or
regulation.
For more information, please contact:
MorphoSys AG
Alexandra Goller
Associate Director Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Dr. Claudia Gutjahr-Löser
Investor Relations Officer
Tel: +49 (0) 89 / 899 27-404
[email protected]
---------------------------------------------------------------------------
Additional features:
Document: http://n.eqs.com/c/fncls.ssp?u=KXNBMCAOYV
Document title: Media Release
---------------------------------------------------------------------------
17.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: [email protected]
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
686667 17.05.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
MorphoSys AG ISIN: DE0006632003 können Sie bei EQS abrufen
Biotechnologie , 663200 , MOR , XETR:MOR